-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Decline in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Decline in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the recipient of a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 30,700 shares, a drop of 39.8% from the December 15th total of 51,000 shares. Based on an average daily trading volume, of 49,300 shares, the short-interest ratio is presently 0.6 days. Approximately 0.3% of the company's shares are short sold.
Candel Therapeutics Stock Up 8.2 %
Shares of CADL traded up $0.17 during mid-day trading on Thursday, reaching $2.25. 32,302 shares of the stock traded hands, compared to its average volume of 47,250. The firm has a market cap of $65.01 million, a price-to-earnings ratio of -5.38 and a beta of 0.10. The stock has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $2.61. Candel Therapeutics has a 12-month low of $1.40 and a 12-month high of $6.81. The company has a quick ratio of 13.41, a current ratio of 13.41 and a debt-to-equity ratio of 0.40.
Get Candel Therapeutics alerts:Candel Therapeutics (NASDAQ:CADL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.23. The firm had revenue of $0.03 million for the quarter. Sell-side analysts expect that Candel Therapeutics will post -1.28 EPS for the current fiscal year.
Institutional Trading of Candel Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Candel Therapeutics in the third quarter worth $53,000. Point72 Asset Management L.P. bought a new stake in shares of Candel Therapeutics in the second quarter worth $2,408,000. Finally, BlackRock Inc. increased its stake in shares of Candel Therapeutics by 15.5% in the first quarter. BlackRock Inc. now owns 132,322 shares of the company's stock worth $674,000 after buying an additional 17,708 shares during the last quarter. Institutional investors own 21.05% of the company's stock.Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Credit Suisse Group cut their price target on shares of Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, December 7th. HC Wainwright assumed coverage on shares of Candel Therapeutics in a report on Friday, December 2nd. They issued a "buy" rating and a $11.00 price target on the stock.
Candel Therapeutics Company Profile
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Read More
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the recipient of a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 30,700 shares, a drop of 39.8% from the December 15th total of 51,000 shares. Based on an average daily trading volume, of 49,300 shares, the short-interest ratio is presently 0.6 days. Approximately 0.3% of the company's shares are short sold.
坎德爾治療, 公司. (NASDAQ: CADL — 獲取評級) 是在十二月份短期利益顯著下降的接收者.截至 12 月 30 日,總共有 30,700 股短息,較十二月十五日的 51,000 股股份下降 39.8%。根據每日平均交易量為 49,300 股,短息比率目前為 0.6 天。約 0.3% 的公司股票賣空。
Candel Therapeutics Stock Up 8.2 %
坎德爾治療股票上漲 8.2%
Shares of CADL traded up $0.17 during mid-day trading on Thursday, reaching $2.25. 32,302 shares of the stock traded hands, compared to its average volume of 47,250. The firm has a market cap of $65.01 million, a price-to-earnings ratio of -5.38 and a beta of 0.10. The stock has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $2.61. Candel Therapeutics has a 12-month low of $1.40 and a 12-month high of $6.81. The company has a quick ratio of 13.41, a current ratio of 13.41 and a debt-to-equity ratio of 0.40.
CADL 股票在周四中間交易期間上漲 0.17 美元,達到 2.25 美元。股票交易手的 32,302 股,相比其平均成交量為 47,250。該公司的市值為 6501 億美元,價格與收益比為 -5.38,測試版為 0.10。該股有 50 天的簡單移動平均線 1.81 美元和 200 天的簡單移動平均線 2.61 美元。坎德爾治療有 12 個月低點 1.40 美元和 12 個月高點 6.81 美元。該公司的快速比率為 13.41,流動比率為 13.41,債務與權益比率為 0.40。
Candel Therapeutics (NASDAQ:CADL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.23. The firm had revenue of $0.03 million for the quarter. Sell-side analysts expect that Candel Therapeutics will post -1.28 EPS for the current fiscal year.
坎德爾治療學(NASDAQ:CADL-獲取評級)上次發布了其季度收益數據,週四,11 月 10 日。該公司報告了該季度的每股盈利(0.30 美元),超過分析師的共識估計(0.53 美元)0.23 美元。該公司本季度的收入為 0.03 萬美元。賣方分析師預計,坎德爾治療學將在當前財政年度發布 -1.28 每股收益。
Institutional Trading of Candel Therapeutics
康德爾治療學的機構交易
Analyst Upgrades and Downgrades
分析師升級和降級
Several research analysts recently commented on the stock. Credit Suisse Group cut their price target on shares of Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, December 7th. HC Wainwright assumed coverage on shares of Candel Therapeutics in a report on Friday, December 2nd. They issued a "buy" rating and a $11.00 price target on the stock.
一些研究分析師最近對該股發表了評論。瑞信集團將康德爾治療學股票的價格目標從 10.00 美元降至 8.00 美元,並在 12 月 7 日(星期三)的一份報告中設定了該股票的「跑贏大市」評級。韋賴特 HC 在 12 月 2 日星期五的一份報告中承擔了坎德爾治療學股份的覆蓋率。他們發布了「買入」評級和 11.00 美元的股票價格目標。
Candel Therapeutics Company Profile
坎德爾治療公司簡介
(Get Rating)
(取得評分)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
康德爾治療有限公司是一家臨床階段生物製藥公司,致力於為癌症患者開發免疫療法。公司開發了 CAN-2409,目前正處於胰腺癌治療的 II 期臨床試驗;治療前列腺癌的 III 期臨床試驗;以及治療肺癌的 II 期臨床試驗,並已完成治療高級膠質瘤的 IB/II 期臨床試驗。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 獲取有關坎德爾治療學(CADL)的研究報告的免費副本
- 高股息收益的必和必拓認為中國推動 23 年增長
- Airbnb 是否正在設置上漲 38%,正如分析師的預測?
- 特斯拉車輛的降價是否意味著 TSLA 股票相同?
- 微軟裁員信號裁員為其他科技公司?
- 快速購買緊固件的不止一個理由
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收康德爾療法的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關坎德爾治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧